| Terminated | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or NCT03425461 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Re NCT03384836 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma NCT03276832 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma NCT03325101 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizuma NCT03050060 | University of Washington | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery NCT03021460 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutate NCT02910700 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma NCT02581930 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Neoadjuvant and Adjuvant Checkpoint Blockade NCT02519322 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma NCT02339571 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Tre NCT02500576 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stag NCT01740557 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metasta NCT02027935 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma NCT01955460 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread NCT02196181 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV NCT02129075 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed NCT01950390 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma NCT02158520 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is NCT01940809 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma NCT01807182 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Mel NCT01708941 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Aerosolized Aldesleukin in Treating Patients With Lung Metastases NCT01590069 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostat NCT01480154 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies NCT01364051 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has NCT01274338 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma NCT01303341 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Rem NCT01258855 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Dinaciclib in Treating Patients With Stage IV Melanoma NCT00937937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery NCT00861913 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patient NCT01989572 | National Cancer Institute (NCI) | Phase 3 |